Liraglutide Reconstitution Calculator

Yes. Liraglutide is an approved subcutaneous GLP-1 receptor agonist for type 2 diabetes at doses up to 1.8 mg/day (Victoza) and for chronic weight management at 3.0 mg/day (Saxenda) in adults meeting BMI/comorbidity criteria; it is also used in pediatric obesity and pediatric type 2 diabetes in selected age groups in the clinical literature and reimbursement reviews (RCT/review). For adult obesity, typical label-aligned use is BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (guideline/review).

For obesity, the standard evidence-based target is 3.0 mg once daily subcutaneously after weekly escalation from 0.6 mg to 1.2 mg, 1.8 mg, 2.4 mg, then 3.0 mg to improve GI tolerability (RCT/review). This escalation pattern is also the dominant real-world protocol and matches case-series/practice studies. Practical titration table (practitioner consensus):

In real-world obesity cohorts, 26-week mean weight loss around 10.9 kg and 52-week mean weight loss around 14.0 kg have been reported, with 85.7% achieving ≥5% loss and 33.3% achieving ≥10% loss at 52 weeks in one bariatric-waitlist cohort (observational). Shorter specialist-clinic data also show clinically meaningful loss by 4-6 months and ~11.5% median total weight loss at 1 year (observational).

Most responders notice appetite reduction within days to 2 weeks and measurable scale loss by 4-8 weeks (community protocol). In real-world studies, weight loss increased with treatment duration: about 3.2 kg at 30 days, 4.5 kg at 60 days, 6.3 kg at 90 days, and 7.8 kg at 180 days in one obesity cohort (observational). A practical checkpoint is 12-16 weeks after reaching or attempting the maintenance dose. If weight loss is <4-5% of baseline body weight by then, continuation is often low-yield and many clinics reassess adherence, tolerability, calorie intake, and whether to switch to semaglutide or tirzepatide (practitioner consensus). Real-world discontinuation commonly reflects inadequate weight loss or weak satiety effect rather than severe toxicity (observational).

Liraglutide works, but it is usually less potent for weight loss and requires daily injections. The ACP 2026 guideline ranks semaglutide and tirzepatide as first-line pharmacologic options for adult obesity, with liraglutide as a lower-line option based on lower-certainty and lower comparative efficacy for weight management (guideline). In pediatric network meta-analysis, liraglutide reduced adiposity versus lifestyle alone, but semaglutide produced larger BMI reductions (network meta-analysis). If cost, access, or tolerance limit semaglutide/tirzepatide use, liraglutide remains a practical second/third-line GLP-1 RA (guideline).

The main adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and early satiety (review/guideline). These are most common during titration and often improve with slower dose escalation (practitioner consensus). Useful tactics (practitioner consensus): smaller meals, lower fat intake during dose increases, stop eating at first fullness, hydrate aggressively, and hold at the current dose an extra 1-2 weeks if nausea is limiting. If symptoms are persistent at 3.0 mg, many users do better at 1.8-2.4 mg than by forcing the full target dose (community protocol).

Key uncommon but important risks are gallbladder disease, pancreatitis, hypersensitivity reactions, and peri-procedural aspiration risk (observational/case report/review). A large cohort found higher adjusted odds of cholelithiasis/choledocholithiasis at 2-3 years and higher cholecystitis/cholecystectomy risk by 3 years for GLP-1 RAs overall, although liraglutide itself was not significantly increased in that subgroup analysis (observational). Pancreatitis appears rare in routine liraglutide practice; the ABCD audit found one case without another clear etiology across 3720 patient-years, about 0.027 per 100 patient-years (audit). Case reports still exist, so new severe persistent upper abdominal pain, especially radiating to the back with vomiting, warrants stopping the drug and urgent evaluation (case report/audit). Hypersensitivity can present as injection-site plaques, pruritus, maculopapular reactions, or more immediate allergy; confirmed cases are published (case report). Because liraglutide delays gastric emptying, there are postmarketing aspiration warnings around anesthesia/deep sedation despite fasting (safety notice).

Use extra caution. GLP-1 agonists can leave residual gastric contents despite standard fasting because they slow gastric emptying, and rare aspiration events have been added to labeling (safety notice). For elective procedures, many anesthesia teams ask patients to hold liraglutide in advance; exact timing varies by center (practitioner consensus). Practical approach (practitioner consensus): tell the surgeon/anesthetist you are on daily liraglutide, especially if you are in dose escalation or have nausea, bloating, reflux, or vomiting. Do not assume ordinary fasting rules fully neutralize risk.

Liraglutide is generally used as long-term chronic therapy if it remains effective and tolerable (guideline/review). Obesity relapse after stopping GLP-1 therapy is common in practice, so long-term continuation is normal when access and tolerability permit (practitioner consensus). At 6-12 months, reassess three things: net weight loss, metabolic improvement, and side-effect burden. If you are not clearly responding, or you need more weight loss than liraglutide is delivering, semaglutide or tirzepatide usually offers a higher ceiling (guideline/network meta-analysis).

Some lean mass loss occurs during GLP-1-mediated weight loss, but fat mass reduction is usually the larger component (network meta-analysis/RCT). Across antidiabetic body-composition trials, liraglutide was associated with significant fat-mass reduction and a smaller but real lean-body-mass reduction (network meta-analysis). In one MRI-based liraglutide trial, the main fat reduction signal was subcutaneous rather than visceral or ectopic fat (RCT). Best mitigation is high protein intake plus resistance training 2-4 times/week (practitioner consensus). This matters more for older adults, people dieting aggressively, and anyone already sarcopenic.

Yes, in selected obesity programs and pediatric diabetes practice, but persistence is a challenge (observational/systematic review). Real-world adolescent obesity data showed significant BMI-SDS reduction, but discontinuation was common, mainly from insufficient weight loss or GI symptoms. Lifestyle support improves continuation substantially; in one pediatric real-world study, combining liraglutide with structured health-behavior/lifestyle treatment markedly increased odds of continuation (OR 18.5, 95% CI 2.0-929.8) and improved BMI response (observational).